HURA Stock Overview

Operates as a biotechnology company that develops novel cell and gene therapies based on distinct and synergistic technology platforms. More details

HURA fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	3/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Trading at 98.3% below our estimate of its fair value

Earnings are forecast to grow 65.49% per year

Risk Analysis

Negative shareholders equity

Makes less than USD$1m in revenue ($0)

Highly volatile share price over the past 3 months compared to the US market

My Notes

Capture your thoughts, links and company narrative

TuHURA Biosciences, Inc. Competitors

Acrivon Therapeutics

NasdaqGM:ACRV

US$187.4m

Gossamer Bio

NasdaqGS:GOSS

US$205.0m

Inozyme Pharma

NasdaqGS:INZY

US$177.9m

Amarin

NasdaqCM:AMRN

US$199.5m

Price History & Performance

Summary of share price highs, lows and changes for TuHURA Biosciences
Historical stock prices
Current Share Price	US$4.09
52 Week High	US$7.93
52 Week Low	US$2.92
Beta	0
1 Month Change	-26.44%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-35.08%

Recent updates

Shareholder Returns

	HURA	US Biotechs	US Market
7D	-10.1%	-2.3%	-2.6%
1Y	n/a	-6.3%	24.5%

Return vs Industry: Insufficient data to determine how HURA performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how HURA performed against the US Market.

Price Volatility

Is HURA's price volatile compared to industry and market?
HURA volatility
HURA Average Weekly Movement	26.4%
Biotechs Industry Average Movement	10.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	17.7%
10% least volatile stocks in US Market	3.1%

Stable Share Price: HURA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine HURA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1993	1	Jim Bianco	tuhurabio.com

TuHURA Biosciences, Inc. operates as a biotechnology company that develops novel cell and gene therapies based on distinct and synergistic technology platforms. The company owns and develops a product portfolio of cellular and gene therapies that can detect, monitor, and control cancer. It offers ImmuneFx, a cancer vaccine; Morphogenesis Allograft Tissue with Compatible HLA (MATCH) stem cell banks; Polymer Antibody Cell Separation System (PACS), a device that captures and releases viable targeted cells from large volumes; and BlueBio, a program for mining microbial compounds from the ocean floor.

TuHURA Biosciences, Inc. Fundamentals Summary

How do TuHURA Biosciences's earnings and revenue compare to its market cap?
HURA fundamental statistics
Market cap	US$171.90m
Earnings (TTM)	-US$19.33m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-8.9x

P/E Ratio

Is HURA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
HURA income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$19.33m
Earnings	-US$19.33m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.46
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-880.5%

How did HURA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/02 20:40
End of Day Share Price	2024/12/31 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

TuHURA Biosciences, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jason McCarthy	Maxim Group

TuHURA Biosciences NasdaqCM:HURA Stock Report